CG oncology, Inc. (CGON)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$61.71-1.33%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge CG oncology, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	522,850
EPS	—	-0.847
Annual ending 2026-12-31
Revenue	—	4.34M
EPS	—	-3.318
Annual ending 2027-12-31
Revenue	—	80.64M
EPS	—	-3.131

Management figures unavailable.

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Maintain stable leadership after recent executive changes	Leadership changes may help the company run better.	Under Pressure	Additional key executive departures in 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Manage operating losses and cash burn near current levels	A supporting condition in CG oncology, Inc.'s published investment case. The stated target is Operating loss no worse than negative $66.4M in 2026-Q1.	Improving	Operating loss worsens beyond negative $70M in 2026-Q1	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Net loss increased from $60.2M in 2026-Q1 to $79.1M in 2026-Q2, driven by higher R&D and G&A expenses due to clinical and headcount growth. Management continues to manage operating losses amid advancing clinical programs, indicating ongoing cost discipline but increasing cash burn. Delivery assessment Oct 24, 2026
Complete and report Phase 3 PIVOT-006 trial topline data	CG Oncology is close to finishing a big Phase 3 trial.	Improving	Topline data not reported by mid-2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management reported that PIVOT-006 Phase 3 trial has accrued most target events and topline data is anticipated in first half 2026. The clinical milestone is on track with management's stated timeline, indicating delivering progress. Delivery assessment Oct 24, 2026
Achieve revenue of about $1.1 billion by end of 2026	The company plans about $1.1 billion in revenue by end of 2026.	Intact	Revenue falls below $1 billion in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-3.13

$-2.82 → $-3.13 · observed estimates

FY2027 revenue$0.08B

$0.09B → $0.08B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-2.82	$85,021,186	11 / 10
2026-07-25	$-2.82	$85,021,186	11 / 10
2026-07-26	$-2.82	$85,021,186	11 / 10
2026-07-27	$-2.82	$85,021,186	11 / 10
2026-07-28	$-2.82	$85,021,186	11 / 10
2026-07-29	$-2.82	$85,021,186	11 / 10
2026-07-30	$-2.82	$85,021,186	11 / 10
2026-07-31	$-2.75	$88,260,970	11 / 13
2026-08-01	$-2.75	$88,260,970	11 / 13
2026-08-02	$-2.75	$88,260,970	11 / 13
2026-08-03	$-2.82	$85,021,186	11 / 10
2026-08-04	$-2.82	$85,021,186	11 / 10
2026-08-05	$-2.82	$85,021,186	11 / 10
2026-08-06	$-2.82	$85,021,186	11 / 10
2026-08-07	$-2.82	$85,021,186	11 / 10
2026-08-08	$-2.82	$85,021,186	11 / 10
2026-08-09	$-2.78	$95,616,060	11 / 12
2026-08-10	$-2.82	$85,021,186	11 / 10
2026-08-11	$-2.85	$115,262,880	12 / 10
2026-08-12	$-2.82	$85,021,186	11 / 10
2026-08-13	$-2.90	$91,537,360	12 / 13
2026-08-14	$-2.82	$85,021,186	11 / 10
2026-08-15	$-2.82	$85,021,186	11 / 10
2026-08-16	$-2.82	$85,021,186	11 / 10
2026-08-17	$-2.82	$85,021,186	11 / 10
2026-08-18	$-2.82	$85,021,186	11 / 10
2026-08-19	$-2.82	$85,021,186	11 / 10
2026-08-20	$-3.03	$88,114,144	11 / 10
2026-08-21	$-3.13	$80,665,628	11 / 10
2026-08-22	$-3.13	$80,665,628	11 / 10
2026-08-23	$-3.13	$80,665,628	11 / 10
2026-08-24	$-3.13	$80,665,628	11 / 10
2026-08-25	$-3.13	$80,665,628	11 / 10
2026-08-26	$-3.13	$80,665,628	11 / 10
2026-08-27	$-3.13	$80,665,628	11 / 10
2026-08-28	$-3.13	$80,665,628	11 / 10
2026-08-29	$-3.13	$80,665,628	11 / 10
2026-08-30	$-3.13	$80,665,628	11 / 10
2026-08-31	$-3.13	$80,665,628	11 / 10
2026-09-01	$-3.13	$80,665,628	11 / 10
2026-09-02	$-3.13	$80,665,628	11 / 10
2026-09-03	$-3.13	$80,665,628	11 / 10
2026-09-04	$-3.13	$80,665,628	11 / 10
2026-09-05	$-3.13	$80,665,628	11 / 10
2026-09-06	$-3.13	$80,665,628	11 / 10
2026-09-07	$-3.13	$80,665,628	11 / 10
2026-09-08	$-3.13	$80,665,628	11 / 10
2026-09-09	$-3.13	$80,665,628	11 / 10
2026-09-10	$-3.13	$80,665,628	11 / 10
2026-09-11	$-3.13	$80,634,700	11 / 10
2026-09-12	$-3.13	$80,634,700	11 / 10
2026-09-13	$-3.13	$80,634,700	11 / 10
2026-09-14	$-3.13	$80,634,700	11 / 10
2026-09-15	$-3.13	$80,634,700	11 / 10
2026-09-16	$-3.13	$80,634,700	11 / 10
2026-09-17	$-3.13	$80,634,700	11 / 10
2026-09-18	$-3.13	$80,634,700	11 / 10
2026-09-19	$-3.13	$80,634,700	11 / 10
2026-09-20	$-3.13	$80,634,700	11 / 10
2026-09-21	$-3.13	$80,634,700	11 / 10
2026-09-22	$-3.13	$80,634,700	11 / 10
2026-09-23	$-3.13	$80,634,700	11 / 10
2026-09-24	$-3.13	$80,634,700	11 / 10
2026-09-25	$-3.13	$80,634,700	11 / 10
2026-09-26	$-3.13	$80,634,700	11 / 10
2026-09-27	$-3.13	$80,634,700	11 / 10
2026-09-28	$-3.13	$80,634,700	11 / 10
2026-09-29	$-3.13	$80,634,700	11 / 10
2026-09-30	$-3.13	$80,634,700	11 / 10
2026-10-01	$-3.13	$80,634,700	11 / 10
2026-10-02	$-3.13	$80,634,700	11 / 10
2026-10-03	$-3.13	$80,634,700	11 / 10
2026-10-04	$-3.13	$80,634,700	11 / 10
2026-10-05	$-3.13	$80,634,700	11 / 10
2026-10-06	$-3.13	$80,634,700	11 / 10
2026-10-07	$-3.13	$80,634,700	11 / 10
2026-10-08	$-3.13	$80,634,700	11 / 10
2026-10-09	$-3.13	$80,634,700	11 / 10
2026-10-10	$-3.13	$80,634,700	11 / 10
2026-10-11	$-3.13	$80,634,700	11 / 10
2026-10-12	$-3.13	$80,634,700	11 / 10
2026-10-13	$-3.13	$80,634,700	11 / 10
2026-10-14	$-3.13	$80,634,700	11 / 10
2026-10-15	$-3.13	$80,634,700	11 / 10
2026-10-16	$-3.13	$80,634,700	11 / 10
2026-10-17	$-3.13	$80,634,700	11 / 10
2026-10-18	$-3.13	$80,634,700	11 / 10
2026-10-19	$-3.13	$80,634,700	11 / 10
2026-10-20	$-3.13	$80,634,700	11 / 10
2026-10-21	$-3.13	$80,634,700	11 / 10
2026-10-22	$-3.13	$80,641,843	11 / 10
2026-10-23	$-3.13	$80,641,843	11 / 10
2026-10-24	$-3.13	$80,641,843	11 / 10

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	15	1
2026-06-01	15	1
2026-07-01	15	1
2026-08-01	14	1
2026-09-01	14	1
2026-10-01	14	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 14 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Maintain stable leadership after recent executive changesPublished status: Under Pressure
Manage operating losses and cash burn near current levelsDirect metric needs a verified mapping
Complete and report Phase 3 PIVOT-006 trial topline dataDirect metric needs a verified mapping
Achieve revenue of about $1.1 billion by end of 2026Direct metric needs a verified mapping

Next proof point

Nov 13, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.9%Typical daily move · historical

Downside history

-27.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

CG oncology, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a clinical-stage biotechnology company, so the thesis depends on trial results and regulatory progress rather than established earnings. The long-term thesis is in a watch state: management is progressing on key milestones, but recent performance is weak and risk has risen.

What's priced into CG oncology, Inc.

The evidence snapshot provides no valuation measure or specific account of market expectations, so whether CGON is cheap, fair, or expensive versus peers is unclear. It also reports low fragility, meaning no flagged signals that expectations are unusually concentrated or vulnerable.

What the fundamentals likely do

Near term, consecutive earnings misses and a high stated risk of another miss leave performance uncertain; the risk label recently moved from moderate to elevated. Over the multi-year view, the Phase 3 trial and planned regulatory filing are important progress points, while the company reports cash sufficient to fund operations through 2029.

What CG oncology, Inc. hinges on

The thesis hinges on the PIVOT-006 trial data and the expected Q4 2026 BLA submission, which is a regulatory application. A guidance cut or further weak results would add to execution concerns; stronger results from major healthcare peers could support sector momentum, though that is not company-specific evidence.